FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer.

摘要

Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration (FDA) has approved Avastin~R (bevacizumab) to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), the most common type of lung cancer. The approval is based on a Phase III study (E4599) that showed Avastin in combination with chemotherapy resulted in a 25% improvement in overall survival compared to chemotherapy alone (based on a hazard ratio of 0.80).